The effect of Aliskiren on exercise capacity in older patients with heart failure and preserved ejection fraction: A randomized, placebo-controlled, double-blind trial - 18/06/18
Doi : 10.1016/j.ahj.2018.03.019
Bharathi Upadhya, MD a, Peter H. Brubaker, PhD b, Timothy M. Morgan, PhD c, Joel D. Eggebeen, MS d, Geoffrey T. Jao, MD a, Kathryn P. Stewart, RT, RDMS a, Dalane W. Kitzman, MD a, ⁎ 
a Cardiovascular Medicine Section, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC
b Department of Health and Exercise Science, Wake Forest University, Winston-Salem, NC
c Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC
d Emory University School of Medicine, Atlanta, GA
⁎Reprint requests: Dalane W. Kitzman, MD, Kermit Glenn Phillips II Chair in Cardiovascular Medicine, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157–1045.Kermit Glenn Phillips II Chair in Cardiovascular Medicine, Wake Forest School of Medicine, Medical Center BoulevardWinston-SalemNC27157–1045
Abstract |
In older patients (70 ± 7 years) with chronic well-compensated heart failure with preserved ejection and controlled blood pressure, 6 months treatment with aliskiren (direct renin inhibitor) showed non-significant trends for modest improvements in peak exercise oxygen consumption (14.9 ± 0.2 mL kg−1 min−1 versus 14.4 ± 0.2 mL kg−1 min−1; P = .10, trend) and ventilatory anaerobic threshold (888 ± 19 mL/min versus 841 ± 18 mL/min; P = .08).
Le texte complet de cet article est disponible en PDF.Plan
| ClinicalTrials.gov Identifier: NCT00982033. |
|
| Funding Sources: This study was funded, in part, by an investigator-initiated grant from Novartis Pharmaceuticals. However, Novartis had no role in study conduct, data analysis, interpretation, or manuscript generation. Also funded in part by: NIH R01AG18915 and R01AG045551; The Claude D. Pepper Older Americans Independence Center of Wake Forest University NIH P30AG21332; Clinical and Translational Science Institute of Wake Forest School of Medicine NIH UL1TR001420; and the Kermit G. Phillips II Chair in Cardiovascular Medicine of Wake Forest School of Medicine. |
© 2018
Publié par Elsevier Masson SAS.
Vol 201
P. 164-167 - juillet 2018 Retour au numéro
Article précédent
- Stroke type and severity in patients with subclinical atrial fibrillation: An analysis from the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial (ASSERT)
- Kanjana S. Perera, Mukul Sharma, Stuart J. Connolly, Jia Wang, Michael R. Gold, Stefan H. Hohnloser, Chu Pak Lau, Isabelle C. Van Gelder, Carlos Morillo, Alessandro Capucci, Carsten W. Israel, Gluca Botto, Jeffery S. Healey
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?